Business Context and Reporting Period
Company: Inspire Medical Systems, Inc.
Filing Type: Form 8-K (Current Report)
Date: August 6, 2024
Reporting Period: Second Quarter ended June 30, 2024
This filing serves as a current report to announce the release of financial results for the quarter ended June 30, 2024, and to disclose a new share repurchase authorization. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The Form 8-K text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this filing.
Material Changes and Corporate Actions
- Share Repurchase Authorization: On August 6, 2024, the Board of Directors authorized the repurchase of up to $150.0 million of the Company's outstanding common stock.
- Financial Results Announcement: The Company issued a press release announcing its financial results for the quarter ended June 30, 2024.
- Investor Relations: The Company scheduled participation in investor and analyst meetings for August and September 2024, with presentation materials provided as Exhibit 99.2.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook figures, or detailed risk factors. It references the existence of presentation materials (Exhibit 99.2) used for investor meetings, which likely contain forward-looking statements, but the content of those statements is not included in the 8-K text. The filing includes standard disclaimers that the information in Items 2.02 and 7.01 is not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2024 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Presentation Materials) for management's updated guidance and strategic outlook.
- Verify the terms and conditions of the $150.0 million share repurchase program announced in Exhibit 99.3.
- Check the Company's Investor Relations website for the full text of the referenced exhibits.